top of page

Bayer and Evotec join hands to develop new treatments for kidney diseases

Bayer and German firm Evotec have partnered to develop to new treatments for kidney diseases.

Under the five-year, multi-target research partnership, the companies will develop several clinical candidates for the treatment of chronic kidney disease in diabetes patients.

Both parties will contribute novel drug targets and a set of technology platforms, and will share responsibilities during preclinical development.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page